Molgramostim

6 trials 3 recruiting Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

1 Completed trials

4 Sponsors

11 Countries

Phase III

Phase I/II

Phase I

Phase I (Other)

Phase III: 2 Phase I/II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Sponsors using this IMP

Region Sjaelland 3 Reponex Pharmaceuticals A/S 3 Savara ApS 2 Oslo University Hospital HF 1

All trials

6 total

Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients … Not authorised

2024-520317-49-00 Phase I (Other) 1 country Region Sjaelland; Reponex Pharmaceuticals A/S
Intraperitoneal treatment with fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor in patients … Pending

2024-520317-49-02 Phase I (Other) 1 country Region Sjaelland; Reponex Pharmaceuticals A/S
A study to test Inhaled Molgramostim in Pediatric Participants with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Recruiting

2024-512039-66-00 Phase III 1 country Savara ApS
PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI Recruiting

2024-517047-30-01 Phase I 1 country Oslo University Hospital HF
A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch an… Recruiting

2024-517764-38-00 Phase I/II 1 country Region Sjaelland; Reponex Pharmaceuticals A/S
Once-daily inhaled molgramostim nebulizer solution in aPAP Ended

2024-511052-41-00 Phase III 9 countries Savara ApS

Showing 1–6 of 6 trials

← All drugs A–Z